In the News

NOVEMBER 13, 2024

TRex Bio Raises $84M to Compete in Crowded Immune Drug Field

See More →

NOVEMBER 13, 2024

Lilly, J&J, Pfizer Pile in on Treg-Focused Biotech’s $84M Round

See More →

NOVEMBER 13, 2024

TRexBio Raises $84M to Take In-house Immune Program into the Clinic

See More →

JUNE 19, 2023

TRexBio: restoring tissue immune homeostasis via Treg modulation

See More →

JANUARY 9, 2023

Exclusive: Eli Lilly boosts inflammatory disease pipeline, licenses three candidates from TRexBio

See More →

JANUARY 10, 2022

Jurassic Ambitions: TRexBio Targets Tregs with Janssen Collaboration

See More →